Clinical Trials Logo

Clinical Trial Summary

Elderly subjects are at greater risk of thrombophlebitis than the general population, but also of bleeding when anticoagulant therapy is initiated. Enoxaparin is one of the most widely used anticoagulants in the management of venous thromboembolism in the world. Its use is not codified in the elderly, because too few studies have been carried out in people over 75 years old. For several years, Enoxaparin in curative treatment has been administered at a reduced dosage of 4000 IU twice a day (and not at a standard dose of 100 IU / kg) at the Geriatrics center of the CRHU in Strasbourg with the clinical impression of a reduction the risk of serious bleeding without reduction in therapeutic efficacy in this very elderly population. Confirmation of a reduction in the risk of bleeding at this dosage could be the start of a change in prescribing practices, towards a more suitable dosage in the elderly.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05150314
Study type Observational
Source University Hospital, Strasbourg, France
Contact Alexandre BOUSSUGE, MD
Phone 33 3 88 11 54 61
Email alexandre.boussuge@chru-strasbourg.fr
Status Recruiting
Phase
Start date November 18, 2021
Completion date April 18, 2023

See also
  Status Clinical Trial Phase
Completed NCT04414332 - Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
Recruiting NCT03206372 - Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Not yet recruiting NCT02188056 - Observational Prospectif Monocentric Registry of Patients Suffering From VIE N/A
Completed NCT04846725 - Predictors of Attempted Inferior Vena Cava Filters Retrieval.
Completed NCT01729559 - Venous Thromboembolic Prophylaxis After Major Trauma: A Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Phase 4
Completed NCT01466426 - The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study) N/A
Active, not recruiting NCT05396157 - Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
Active, not recruiting NCT00691470 - Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation Phase 2/Phase 3
Completed NCT04824118 - Clotting Parameters After Medical Abortion
Recruiting NCT03887806 - Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study
Not yet recruiting NCT06232551 - Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism N/A
Recruiting NCT05993533 - Comparison of the 'CTR' Ratio With Standard Haemostasis Parameters in the Follow-up of Patients Undergoing Heparin Therapy
Not yet recruiting NCT05515549 - Value of D-dimer Combined With Other Thrombus Molecular Markers in Risk Assessment of VTE in Hospitalized Patients
Recruiting NCT04211181 - CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism N/A
Completed NCT04818151 - Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Recruiting NCT05089227 - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study Phase 2
Completed NCT03894878 - Association Between Genetic Variant Scores and Warfarin Effect
Completed NCT00556426 - Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter. N/A
Not yet recruiting NCT04158973 - CHIPs-VTE Study in Hospitalized Patients With Lung Cancer N/A